Quarterly report pursuant to Section 13 or 15(d)

Reverse Merger (Tables)

v3.10.0.1
Reverse Merger (Tables) - OncoGenex Pharmaceuticals, Inc [Member]
 9 Months Ended
Sep. 30, 2018
Business Acquisition [Line Items]  
Summary of Final Purchase Price

The final purchase price is summarized as follows (dollars in thousands, except per share amounts):

 

Shares of the combined company to be owned by OncoGenex equity holders

 

 

273,671

 

Multiplied by the price per share of OncoGenex stock

 

$

46.20

 

Value of shares of the combined company owned by OncoGenex equity holders

 

$

12,643

 

Fair value of options and warrants assumed

 

$

207

 

Fair value of contingent value rights assumed

 

$

200

 

Total purchase price

 

$

13,050

 

 
Summary of Final Purchase Price Allocation

The final purchase price allocation is as follows (in thousands):

Cash, cash equivalents and marketable securities

 

 

12,376

 

Prepaid expenses and other assets

 

 

518

 

Intangible assets license agreements

 

 

8,610

 

Accounts payable, accrued expenses and other liabilities

 

 

(4,054

)

Deferred tax liability

 

 

(2,928

)

Contingent value rights

 

 

(200

)

Excess negative goodwill

 

 

(1,272

)

Total purchase price

 

 

13,050

 

 
Summary of Pro Forma Results of Operation

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Net loss applicable to common shareholders

 

$

(3,240

)

 

$

(9,730

)

 

$

(9,050

)

 

$

(10,100

)

Net loss per share-basic and diluted

 

$

(0.71

)

 

$

(13.47

)

 

$

(3.70

)

 

$

(41.48

)

Weighted average shares

 

 

4,533,943

 

 

 

722,583

 

 

 

2,448,962

 

 

 

243,510